Envelope surface glycoprotein gp120
|
env
|
The binding of soluble HIV-1 gp120 to TLR2 or TLR4 results in upregulation of the TNF-alpha and IL-8 production through NF-kappaB activation |
PubMed
|
|
env
|
Treatment of HIV-1 gp120 to astroglia displays significant increases in TLR2 |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
Fully processed HIV-1 Env protein, once expressed on the cellular membrane, inhibits TLR2 activation |
PubMed
|
|
env
|
HIV-1 gp41 binds TLR2 (from TZM-bl-2 cell lysates) |
PubMed
|
|
env
|
siRNA knockdown of TLR2 in a HIV-1 gp41-exposed TLR2 transgene cell line, TZM-bl-2, decreases IL-8 production |
PubMed
|
|
env
|
Exposure of anti-TLR2 antibody-treated primary T cells to HIV-1 gp41 decreases IL-8 production |
PubMed
|
|
env
|
Exposure of TLR2 transgene cell lines (TZM-bl-2, HEK293-TLR2/1, HEK293-TLR2/6) to HIV-1 gp41 increases the production of IL-8 |
PubMed
|
|
env
|
The HIV-1 gp41 transmembrane domain (TMD) inhibits the interaction between the TMDs of TLR2 and TLR6 in vitro |
PubMed
|
|
env
|
The transmembrane domain (TMD) of HIV-1 gp41 directly interacts with the TLR2 TMD within the membrane, partially through its GxxxG dimerization motif |
PubMed
|
|
env
|
The HIV-1 gp41 transmembrane domain inhibits TLR2-induced activation of ERK1/2, and secretion of TNF-alpha, MCP-1, and IL-6 |
PubMed
|
|
env
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|
Nef
|
nef
|
HIV-1 Nef-mediated upregulation of TLR2 increases regulatory T cells (Tregs) and inhibits the proliferation of PBMCs |
PubMed
|
|
nef
|
HIV-1 Nef upregulates TLR2 expression via NF-kappaB activation in THP-1 cells |
PubMed
|
Tat
|
tat
|
Treatment of HIV-1 Tat to astroglia displays significant increases in TLR2 expression |
PubMed
|
capsid
|
gag
|
HIV-1 CA binds TLR2 (from TZM-bl-2 cell lysates) |
PubMed
|
|
gag
|
Exposure of the TLR2 transgene cell line, HEK293-TLR2/6, to HIV-1 CA (p24) increases the production of IL-8 BUT NOT in the TLR2 transgene cell lines, TZM-bl-2 and HEK293-TLR2/1 |
PubMed
|
|
gag
|
Exposure of anti-TLR2 antibody-treated primary T cells to HIV-1 CA (p24) decreases IL-8 production |
PubMed
|
|
gag
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|
matrix
|
gag
|
HIV-1 MA (p17) binds TLR2 (from TZM-bl-2 cell lysates) |
PubMed
|
|
gag
|
siRNA knockdown of TLR2 in a HIV-1 MA (p17)-exposed TLR2 transgene cell line, TZM-bl-2, decreases IL-8 production |
PubMed
|
|
gag
|
Exposure of anti-TLR2 antibody-treated primary T cells to HIV-1 MA (p17) decreases IL-8 production |
PubMed
|
|
gag
|
Exposure of TLR2 transgene cell lines (TZM-bl-2, HEK293-TLR2/1, HEK293-TLR2/6) to HIV-1 MA (p17) increases the production of IL-8 |
PubMed
|
|
gag
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|